Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
FY 2022-23
Summary
An essential component of vaccine efficacy against viruses is activating cell-mediated immunity, particularly cytolytic T cells. This is primarily mediated by dendritic cells in a process called cross presentation whereby extracellular proteins are processed and loaded onto a major histocompatibility complex class I (MHC-I) molecule, priming cytolytic T cells against a specific viral peptide. However, the molecular pathways involved in cross presentation is not completely understood, regardless that it is essential for generating cytolytic T cells which recognize the most immunogenic viral peptides. Recent work has identified that a different immune cell, called type two innate lymphoid cells (ILC2s), are also capable of MHC-I antigen cross-presentation of cytotoxic T cells. This represents a paradigm shift in the understanding of cell-mediated immunity against viral infections and tumours, as ILC2s were previously thought to only be involved in allergic responses and helminth clearance. Therefore, the main goal of this project is to develop a molecular understanding of the ILC2 cross-priming ability and investigate its role on the peptides recognized by cytolytic T cells during influenza vaccination. This will be achieved by performing single-cell RNA sequencing to explore the genes expressed by ILC2s and use CRISPR-Cas9 gene technology to specifically knockout out genes that may be essential in cross-priming. Then, mice containing certain types of ILC2s will be vaccinated against influenza, comparing the peptides recognized by cytolytic T cells. Elucidating candidate genes involved cross-priming will increase our understanding and the predictability of vaccine and cancer immune responses, opening numerous avenues for immunotherapeutic development.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486527
Name
Besoiu Stephanie
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Anti-Tumor Immunity; Antigen Presentation; Crispr-Cas9; Cross Presentation; Cytolytic T Lymphocytes; Functional Genomics; Group 2 Innate Lymphoid Cells; Influenza; Vaccine Immunodominance; Vaccine Immunology
Abstract
An essential component of vaccine efficacy against viruses is activating cell-mediated immunity, particularly cytolytic T cells. This is primarily mediated by dendritic cells in a process called cross presentation whereby extracellular proteins are processed and loaded onto a major histocompatibility complex class I (MHC-I) molecule, priming cytolytic T cells against a specific viral peptide. However, the molecular pathways involved in cross presentation is not completely understood, regardless that it is essential for generating cytolytic T cells which recognize the most immunogenic viral peptides. Recent work has identified that a different immune cell, called type two innate lymphoid cells (ILC2s), are also capable of MHC-I antigen cross-presentation of cytotoxic T cells. This represents a paradigm shift in the understanding of cell-mediated immunity against viral infections and tumours, as ILC2s were previously thought to only be involved in allergic responses and helminth clearance. Therefore, the main goal of this project is to develop a molecular understanding of the ILC2 cross-priming ability and investigate its role on the peptides recognized by cytolytic T cells during influenza vaccination. This will be achieved by performing single-cell RNA sequencing to explore the genes expressed by ILC2s and use CRISPR-Cas9 gene technology to specifically knockout out genes that may be essential in cross-priming. Then, mice containing certain types of ILC2s will be vaccinated against influenza, comparing the peptides recognized by cytolytic T cells. Elucidating candidate genes involved cross-priming will increase our understanding and the predictability of vaccine and cancer immune responses, opening numerous avenues for immunotherapeutic development.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Besoiu, Stephanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~